Profenofos


Curated chemical-gene interactions from CTD
Entrez gene IDGene symbolInteraction typeReference
10069 RWDD2B Increases expression PMID:17569032
1543 CYP1A1 Decreases activity PMID:20183062
1544 CYP1A2 Decreases activity PMID:20183062
1544 CYP1A2 Increases expression PMID:22310298
1548 CYP2A6 Increases expression PMID:22310298
1555 CYP2B6 Decreases activity PMID:22310298
1555 CYP2B6 Increases expression PMID:22310298
1559 CYP2C9 Decreases activity PMID:22634058
1571 CYP2E1 Decreases activity PMID:22634058
1576 CYP3A4 Increases activity PMID:22310298
1576 CYP3A4 Increases expression PMID:22310298
1583 CYP11A1 Increases expression PMID:17569032
1586 CYP17A1 Increases expression PMID:17569032
1588 CYP19A1 Decreases expression PMID:18828448
2166 FAAH Decreases activity PMID:11350214
23024 PDZRN3 Increases expression PMID:17569032
2643 GCH1 Decreases expression PMID:17569032
266682 CYP3A2 Decreases expression PMID:18828448
2903 GRIN2A Decreases expression PMID:17569032
29277 CYP2C11 Decreases expression PMID:18828448
29982 NRBF2 Decreases expression PMID:17569032
3240 HP Increases expression PMID:17569032
3915 LAMC1 Decreases expression PMID:17569032
4162 MCAM Decreases expression PMID:17569032
43 ACHE Decreases activity PMID:16978018; PMID:21251949; PMID:33651127; PMID:30625376; PMID:33651127
4642 MYO1D Decreases expression PMID:17569032
4745 NELL1 Decreases expression PMID:17569032
51179 HAO2 Increases expression PMID:17569032
57552 NCEH1 Decreases activity PMID:16978018
590 BCHE Decreases activity PMID:9890196
5997 RGS2 Increases expression PMID:17569032
64231 MS4A6A Increases expression PMID:17569032
6505 SLC1A1 Decreases expression PMID:17569032
6647 SOD1 Increases expression PMID:23495063
6770 STAR Increases expression PMID:17569032
8289 ARID1A Decreases expression PMID:17569032
847 CAT Increases expression PMID:23495063
91851 CHRDL1 Decreases expression PMID:17569032
9970 NR1I3 Increases expression PMID:22310298

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.